Imperial College London
Alternate

Jiri Pavlu

Faculty of Medicine, Department of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 8117j.pavlu Website

 
 
//

Location

 

Leuka Building R2.20Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pavlu:2017:10.1002/cncr.30604,
author = {Pavlu, J and Labopin, M and Zoellner, AK and Sakellari, I and Stelljes, M and Finke, J and Fanin, R and Stuhler, G and Afanasyev, BV and Bloor, AJ and Anagnostopoulos, A and Mohty, M and Giebel, S and Nagler, A},
doi = {10.1002/cncr.30604},
journal = {Cancer},
pages = {1965--1970},
title = {Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT},
url = {http://dx.doi.org/10.1002/cncr.30604},
volume = {123},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Patients with primary refractory acute lymphoblastic leukemia (PREF ALL) who fail to achieve a complete remission(CR) after 2 courses of chemotherapy have a dismal prognosis without undergoing allogeneic hematopoietic cell transplantation(HCT). To the authors’ knowledge, there currently are no data regarding factors influencing transplantation outcomes. METHODS: Theauthors retrospectively studied outcomes of transplantation for cases of PREF ALL reported to European Society for Blood andMarrow Transplantation registry. Eligibility criteria for the current analysis included adult patients who underwent their first HCT forPREF ALL between 2000 and 2012. PREF disease was defined as the failure to achieve a morphological CR after 2 courses of inductionchemotherapy. RESULTS: Data regarding 86 adult patients were analyzed. With a median follow-up of 106 months, the probabilityof survival was 36% at 2 years and 23% at 5 years. The probability of leukemia-free survival was 28% and 17%, respectively, and theprobability of nonrecurrence mortality was 20% and 29%, respectively, at 2 years and 5 years. For 66 patients who achieved a CR(77%), the survival at 2 years and 5 years was 36% and 29%, respectively. In multivariate analysis, use of total body irradiation wasfound to be associated with improved survival. Total body irradiation and infusion of female hematopoietic cells into male recipientswas associated with improved leukemia-free survival. These findings were incorporated into a scoring system that identified 3 groups(those with 2, 1, or no prognostic factors) with survival rates of 57%, 22%, and 8%, respectively. CONCLUSIONS: Although overall thesepatients would clearly benefit from the introduction of novel antileukemic therapies, the data from the current study support the useof allogeneic HCT in selected patients with PREF ALL.
AU  - Pavlu,J
AU  - Labopin,M
AU  - Zoellner,AK
AU  - Sakellari,I
AU  - Stelljes,M
AU  - Finke,J
AU  - Fanin,R
AU  - Stuhler,G
AU  - Afanasyev,BV
AU  - Bloor,AJ
AU  - Anagnostopoulos,A
AU  - Mohty,M
AU  - Giebel,S
AU  - Nagler,A
DO  - 10.1002/cncr.30604
EP  - 1970
PY  - 2017///
SN  - 0008-543X
SP  - 1965
TI  - Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT
T2  - Cancer
UR  - http://dx.doi.org/10.1002/cncr.30604
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401841700014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/49942
VL  - 123
ER  -
Download